Patients with oligometastatic colorectal cancer (5 metastases or less) receive a combination of systemic treatment and often local treatment, such as surgery, radiofrequency ablation and more recently stereotactic body radiotherapy. The aim of this study is to register the results and side effects of stereotactic body radiotherapy (SBRT) by means of helical tomotherapy in the treatment of oligometastatic colorectal cancer. The trial has two cohorts. Patients in cohort I get consolidation SBRT after best response on first line chemotherapy. Patients in cohort II get SBRT when there is progression under, or no indication for (further) chemotherapy. The primary endpoint is to evaluate the metabolic complete remission rate three months after the start of radiotherapy.
Study Type
OBSERVATIONAL
Enrollment
53
UZ Brussel, Vrije Universiteit Brussel, dienst Radiotherapie
Brussels, Belgium
Metabolic complete remission rate
Time frame: Three months
Acute toxicity
Time frame: Three months
Progression free survival
Time frame: Three to thirty six months
Local control
Time frame: Three to thirty six months
Survival
Time frame: Three to thirty six months
Late toxicity
Time frame: Three to thirty six months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.